MarcusToday On the Couch Podcast: Biotech Special

Listen to the On the Couch biotech special podcast. Host Henry Jennings sits down with fund manager BioScience Managers and biotechs Biotron and Pharmaxis to discuss what makes a successful biotech and how to invest successfully in the cutting edge of medical science and drug treatments. In this ‘On the Couch’ special, Henry Jennings sits down with two […]

Tragedy behind Australia’s world-class burns technology treatment RECELL: Robert Gottliebsen

The Australian, Tuesday, November 8, 2022, Link Here: One of Australia’s best known, and most successful medical breakthroughs has been the burns treatment process developed in Western Australia, which was highlighted after the 2002 Bali bombings. But it is also one of the most tragic. The US has now embraced the Australian technology as its […]

BioScience Managers Announces the Appointment of Dr. David Atkins as Managing Partner to Continue its Growth in Digital Health

Melbourne, Australia and London, UK – October 13, 2022 ….. BioScience Managers, the international healthcare investment firm, is pleased to announce the appointment of David Atkins MBA PhD in the role of Managing Partner. Working alongside founder and Managing Partner, Jeremy Curnock Cook, David will be responsible for driving the future growth of BioScience Managers […]

US FDA Clears IND for Cynata’s Phase 2 Clinical Trial of CYP-001 in GvHD

Link to full article Key Highlights: • US FDA has cleared Cynata’s IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company • Phase 2 clinical study in aGvHD expected to commence subsequent to customary and satisfactory completion of negotiations with […]

Parkinson’s patients benefit from revolutionary watch on the NHS to manage care at home

Link to full article Patients with Parkinson’s disease are being given life-changing smart watches that allow doctors to remotely assess their condition in a pioneering project to revolutionise NHS care. The cutting-edge gadget containing sensors, known as a Parkinson’s Kinetigraph (PKG), is worn around the clock for six days to monitor patients’ movements at home. […]

Cynata Advances Clinical Trial in Diabetic Foot Ulcers

Link to full article Melbourne, Australia; 21 April 2022: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinicalstage biotechnology company specialising in cell therapeutics, is pleased to announce enrolment of initial patients in a clinical trial of CYP-006TK as a potential treatment for diabetic foot ulcers (DFU). Subjects are now being followed as planned for […]


1 April 2022: As leading healthcare investors, BioScience Managers welcomes the on-going bipartisan support for Australia’s developing biotechnology sector following the March Federal Budget. However, BioScience Managers is calling for greater backing from Australia’s investment community, particularly institutional investors, to retain the benefits of Australian innovation within Australia as a critical part our post COVID-19 pandemic recovery. […]

Saluda Medical Receives FDA Approval for the Evoke® Spinal Cord Stimulation System to Treat Chronic Intractable Pain

Link to full article Artarmon, Australia – March 8, 2022 – Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, today announced it received full approval from the United States Food and […]

CalciMedica Announces Publication of Peer-Reviewed Paper in The Journal of Physiology

Link to full article March 10, 2022 Study Supports Development of CRAC Channel Inhibitors for Acute Pancreatitis Study indicates that Orai1 inhibition prevents impaired ductal cell function in acute pancreatitis (AP) Data describes underlying biological mechanisms that may explain key result in a Phase 2a trial of AuxoraTM in patients with AP with systemic inflammatory response […]